文献速递前列腺癌

在线决策辅助工具可提高低危前列腺癌患者主动监测的采纳率:Navigate随机对照试验

An Online Treatment Decision Aid for Men with Low-risk Prostate Cancer Eligible for Active Surveillance and Their Partners Increases the Uptake of Active Surveillance: The Navigate Randomised Controlled Trial.
PubMed 文献 · Eur Urol Oncol · 2025-04-12

这项在澳大利亚开展的平行组随机对照试验纳入302例适合主动监测的低危前列腺癌患者,1:1随机接受在线决策辅助工具Navigate或国家前列腺癌网站常规信息。结果显示,Navigate组自报主动监测采纳率为90.6%,显著高于常规组的79.0%(p=0.008),且决策准备度更优。伴侣间未见显著差异,长期结局未测量。

要点

  • 在线决策辅助工具Navigate使低危前列腺癌患者主动监测采纳率提高至90.6%。
  • 常规信息组主动监测采纳率为79.0%,组间差异有统计学意义。
  • Navigate组决策准备度显著优于常规组,伴侣间未见显著差异。

核心结论

  • 提供在线决策辅助工具可使低危前列腺癌患者主动监测采纳率高于标准资源,并提高决策准备度。

研究设计与样本

  • 平行组、前瞻性、随机对照试验,2017年5月至2021年5月从参与癌症中心招募患者。
  • 纳入标准为近期低危前列腺癌诊断、未决定治疗、临床适合主动监测,伴侣可同时入组。
  • 302例合格患者1:1随机至Navigate在线决策辅助工具组(n=153)或国家前列腺癌网站常规护理组(n=149),按站点/招募方式分层。
  • 伴侣按对应患者分组分配至Navigate组(n=70)或常规组(n=49)。
  • 基线及基线后1、2、6个月进行评估,采用意向性治疗分析。

主要发现

  • 1个月时自报主动监测作为一线治疗的比例:Navigate组90.6%,常规组79.0%(p=0.008)。
  • Navigate组决策准备度显著更高(p<0.001)。
  • 伴侣两组间未见显著差异。

关键数值与推荐

  • 主要结局为1个月时自报主动监测采纳率,Navigate组90.6% vs 常规组79.0%(p=0.008)。
  • 决策准备度组间比较p<0.001,Navigate组更优。

临床怎么用

  • 对适合主动监测的低危前列腺癌患者,可提供在线决策辅助工具以促进主动监测的采纳。
  • 决策辅助工具有望通过提高主动监测采纳率减少治疗相关并发症。
  • 需开展实施性研究评估将Navigate整合入标准诊疗的可行性。

局限性

  • 未测量长期结局。
  • 伴侣间未见显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Evidence suggests that curative treatment for low-risk prostate cancer (LRPC) has no survival benefits over active surveillance (AS); thus, treatment choice becomes a value-sensitive decision. Decision aids (DAs) have the potential to facilitate this process, yet no DA has been tailored to the Australian health care system or population. This study aims to evaluate the impact of an online DA (Navigate) on the uptake of AS, quality of life, and decision-making in Australia. METHODS: This parallel-group, prospective, randomised controlled trial recruited men (from May 2017 to May 2021) from participating cancer centres, via self-referral, or via clinician referral. The inclusion criteria were the following: a recent LRPC diagnosis, no decision on treatment, and clinical suitability for AS. Partners could also enrol. Assessments were undertaken at baseline (before decision) and after baseline (1, 2, and 6 mo). Participants were randomised 1:1 to Navigate (online DA, intervention) or a national prostate cancer website (usual care), stratified by the site/recruitment method. Partners were allocated to the group matching their respective partners. The primary outcome was self-reported uptake of AS for first-line treatment at 1 mo. The secondary outcomes included decision-making preparedness; decisional conflict, regret, and satisfaction; illness communication; and prostate cancer-specific quality of life. Intention-to-treat analyses were conducted. KEY FINDINGS AND LIMITATIONS: Of the 619 patients referred, those eligible (n = 302) were randomised to either Navigate (n = 153) or usual care (n = 149), with no significant between-group differences at baseline. The proportion of men self-reporting AS versus another treatment was 90.6% (Navigate) versus 79.0% (usual care; p = 0.008). Navigate participants also reported greater decision-making preparedness (p < 0.001). Partners were allocated to Navigate (n = 70) or usual care (n = 49); no significant between-group differences were found. Longer-term outcomes were not measured. CONCLUSIONS AND CLINICAL IMPLICATIONS: Providing men with an online DA resulted in higher uptake of AS for LRPC than standard resources and in increased decision-making preparedness. By increasing the uptake of AS, DAs may help reduce treatment-related morbidity. Implementation research assessing the possibility of integrating Navigate into standard care is needed.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Schofield P, Quinn S, Richards N, et al. An Online Treatment Decision Aid for Men with Low-risk Prostate Cancer Eligible for Active Surveillance and Their Partners Increases the Uptake of Active Surveillance: The Navigate Randomised Controlled Trial. Eur Urol Oncol. 2025. PMID: 40222891. doi:10.1016/j.euo.2025.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。